生物制剂作为炎症性肠病治疗药物的有吸引力的目标
Jia-Chen Xue1, Xiao-Ting Hou2, Yu-Wei Zhao3
1Department of Nuclear Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, China; Key Laboratory of Microenvironment Regulation and Immunotherapy of Urinary Tumors in Liaoning Province, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, China.
炎症性肠病 (IBD) 的治疗方法正在超越传统药物. 生物药物,如抗瘤缩因子α和vedolizumab,为性结肠炎和克罗恩病的管理提供了新的选择.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠道疾病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),涉及慢性肠道炎症,原因复杂且不清楚.
- 传统的IBD治疗方法,如5-aminosalicylates,葡萄糖皮质类药物和免疫抑制剂都有局限性.
研究的目的:
- 审查目前用于IBD的生物疗法的疗效和安全性.
- 分析管理炎症性肠病的临床挑战.
主要方法:
- 对IBD的主要生物疗法的审查.
- 对临床试验数据和治疗结果的分析.
- 对安全性和有效性概况的全面评估.
主要成果:
- 抗瘤坏死因子α是适度至重度IBD的第一线治疗方法.
- 抗整合素抗体,如vedolizumab,对于治疗耐药或不耐受病例至关重要.
- 目前正在进行的临床试验正在评估IBD的新生物药物.
结论:
- 生物疗法在IBD治疗方面取得了重大进展.
- 了解这些治疗方法的有效性,安全性和挑战对于患者护理至关重要.
- 对新生物药物的进一步研究正在进行中.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
